GB201504565D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB201504565D0
GB201504565D0 GBGB1504565.1A GB201504565A GB201504565D0 GB 201504565 D0 GB201504565 D0 GB 201504565D0 GB 201504565 A GB201504565 A GB 201504565A GB 201504565 D0 GB201504565 D0 GB 201504565D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1504565.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to GBGB1504565.1A priority Critical patent/GB201504565D0/en
Publication of GB201504565D0 publication Critical patent/GB201504565D0/en
Priority to CA2979024A priority patent/CA2979024C/en
Priority to CN201680022416.0A priority patent/CN107531698B/zh
Priority to SG11201707280VA priority patent/SG11201707280VA/en
Priority to ES16715122T priority patent/ES2774052T3/es
Priority to EA201792057A priority patent/EA035739B1/ru
Priority to PT167151224T priority patent/PT3271357T/pt
Priority to MX2017011902A priority patent/MX2017011902A/es
Priority to DK16715122.4T priority patent/DK3271357T3/da
Priority to PCT/JP2016/059782 priority patent/WO2016148306A1/en
Priority to HUE16715122A priority patent/HUE047918T2/hu
Priority to PH1/2017/501699A priority patent/PH12017501699B1/en
Priority to NZ735631A priority patent/NZ735631A/en
Priority to PE2018000126A priority patent/PE20180656A1/es
Priority to TNP/2017/000384A priority patent/TN2017000384A1/en
Priority to GEAP201614608A priority patent/GEP20207095B/en
Priority to US15/558,824 priority patent/US10287286B2/en
Priority to HK18109089.3A priority patent/HK1249512B/en
Priority to AU2016234209A priority patent/AU2016234209B2/en
Priority to EP16715122.4A priority patent/EP3271357B1/en
Priority to BR112017019653-0A priority patent/BR112017019653B1/pt
Priority to KR1020177030091A priority patent/KR102609431B1/ko
Priority to JP2017549107A priority patent/JP6726681B2/ja
Priority to MYPI2017703420A priority patent/MY194873A/en
Priority to UAA201708877A priority patent/UA123668C2/uk
Priority to CR20170468A priority patent/CR20170468A/es
Priority to IL254277A priority patent/IL254277B/en
Priority to CONC2017/0009353A priority patent/CO2017009353A2/es
Priority to CL2017002354A priority patent/CL2017002354A1/es
Priority to DO2017000209A priority patent/DOP2017000209A/es
Priority to ZA2017/06612A priority patent/ZA201706612B/en
Priority to ECIEPI201769696A priority patent/ECSP17069696A/es
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1504565.1A 2015-03-18 2015-03-18 Novel compounds Ceased GB201504565D0 (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds
CR20170468A CR20170468A (es) 2015-03-18 2016-03-17 Compuestos novedosos
TNP/2017/000384A TN2017000384A1 (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors.
GEAP201614608A GEP20207095B (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
SG11201707280VA SG11201707280VA (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
ES16715122T ES2774052T3 (es) 2015-03-18 2016-03-17 Derivados de heteroarilo bicíclicos fusionados que tienen actividad como inhibidores de PHD
EA201792057A EA035739B1 (ru) 2015-03-18 2016-03-17 Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
PT167151224T PT3271357T (pt) 2015-03-18 2016-03-17 Derivados de heteroarilo bicíclico fundido que têm atividade como inibidores de phd
MX2017011902A MX2017011902A (es) 2015-03-18 2016-03-17 Derivados de heteroarilo biciclico fusionado que tienen actividad como inhibidores del dominio de prolil hidroxilasa.
DK16715122.4T DK3271357T3 (da) 2015-03-18 2016-03-17 Fusionerede bicykliske heteroarylderivater med aktivitet som phd-inhibitorer
HK18109089.3A HK1249512B (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
HUE16715122A HUE047918T2 (hu) 2015-03-18 2016-03-17 PHD inhibitor hatású kondenzált biciklusos heteroarilszármazékok
PH1/2017/501699A PH12017501699B1 (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
NZ735631A NZ735631A (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
PE2018000126A PE20180656A1 (es) 2015-03-18 2016-03-17 Derivados de heteroarilo biciclico fusionados con actividad como inhibidores de phd
CA2979024A CA2979024C (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
US15/558,824 US10287286B2 (en) 2015-03-18 2016-03-17 Compounds
AU2016234209A AU2016234209B2 (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as PHD inhibitors
PCT/JP2016/059782 WO2016148306A1 (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
CN201680022416.0A CN107531698B (zh) 2015-03-18 2016-03-17 具有作为phd抑制剂的活性的稠合双环杂芳基衍生物
EP16715122.4A EP3271357B1 (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
BR112017019653-0A BR112017019653B1 (pt) 2015-03-18 2016-03-17 Composto de formula i e composição farmaceutica
KR1020177030091A KR102609431B1 (ko) 2015-03-18 2016-03-17 Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체
JP2017549107A JP6726681B2 (ja) 2015-03-18 2016-03-17 Phd阻害剤としての縮合二環式ヘテロアリール誘導体
MYPI2017703420A MY194873A (en) 2015-03-18 2016-03-17 Fused Bicyclic Heteroaryl Derivatives Having Activity as Phd Inhibitors
UAA201708877A UA123668C2 (uk) 2015-03-18 2016-03-17 Конденсовані біциклічні гетероарильні похідні з активністю інгібіторів пролілгідроксилази
IL254277A IL254277B (en) 2015-03-18 2017-09-03 Fused bicyclic heteroaryl derivatives with activity as inhibitors of the prolyl hydroxylase domain
CONC2017/0009353A CO2017009353A2 (es) 2015-03-18 2017-09-14 Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd
CL2017002354A CL2017002354A1 (es) 2015-03-18 2017-09-15 Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
DO2017000209A DOP2017000209A (es) 2015-03-18 2017-09-18 Derivados de heteroarilo bicíclico fusionados con actividad como inhibidores de phd
ZA2017/06612A ZA201706612B (en) 2015-03-18 2017-10-02 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
ECIEPI201769696A ECSP17069696A (es) 2015-03-18 2017-10-18 Compuestos novedosos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds

Publications (1)

Publication Number Publication Date
GB201504565D0 true GB201504565D0 (en) 2015-05-06

Family

ID=53051992

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1504565.1A Ceased GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds

Country Status (31)

Country Link
US (1) US10287286B2 (enExample)
EP (1) EP3271357B1 (enExample)
JP (1) JP6726681B2 (enExample)
KR (1) KR102609431B1 (enExample)
CN (1) CN107531698B (enExample)
AU (1) AU2016234209B2 (enExample)
BR (1) BR112017019653B1 (enExample)
CA (1) CA2979024C (enExample)
CL (1) CL2017002354A1 (enExample)
CO (1) CO2017009353A2 (enExample)
CR (1) CR20170468A (enExample)
DK (1) DK3271357T3 (enExample)
DO (1) DOP2017000209A (enExample)
EA (1) EA035739B1 (enExample)
EC (1) ECSP17069696A (enExample)
ES (1) ES2774052T3 (enExample)
GB (1) GB201504565D0 (enExample)
GE (1) GEP20207095B (enExample)
HU (1) HUE047918T2 (enExample)
IL (1) IL254277B (enExample)
MX (1) MX2017011902A (enExample)
MY (1) MY194873A (enExample)
NZ (1) NZ735631A (enExample)
PE (1) PE20180656A1 (enExample)
PH (1) PH12017501699B1 (enExample)
PT (1) PT3271357T (enExample)
SG (1) SG11201707280VA (enExample)
TN (1) TN2017000384A1 (enExample)
UA (1) UA123668C2 (enExample)
WO (1) WO2016148306A1 (enExample)
ZA (1) ZA201706612B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2718902C2 (ru) 2016-02-24 2020-04-15 Пфайзер Инк. Производные пиразоло[1,5-а]пиразин-4-ила в качестве jak-ингибиторов
EP3668858A1 (en) 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
DK3808747T3 (da) * 2018-09-13 2025-02-03 Kissei Pharmaceutical Imidazopyridinon-forbindelse
CN110950806A (zh) * 2019-11-14 2020-04-03 安庆博曼生物技术有限公司 四乙基氯化铵催化嘧啶环羟基氯代制备方法
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
US20230322717A1 (en) * 2020-04-20 2023-10-12 Shenzhen Targetrx, Inc. Solid form of pyrazine substituted nicotinamide, and preparation and use thereof
JP7654071B2 (ja) * 2020-10-20 2025-03-31 アムジエン・インコーポレーテツド 複素環スピロ化合物及び使用方法
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
IL312220A (en) 2021-10-28 2024-06-01 Insilico Medicine Ip Ltd Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
JP2025500892A (ja) * 2021-12-17 2025-01-15 アケビア セラピューティクス インコーポレイテッド 選択的phd1阻害剤化合物、組成物、及び使用方法
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
DK135184A (da) * 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
JP2004502691A (ja) 2000-06-30 2004-01-29 ワイス 抗癌薬としての置換トリアゾロピリミジン
JP2010065026A (ja) 2008-08-13 2010-03-25 Ishihara Sangyo Kaisha Ltd ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
HRP20140705T1 (hr) * 2009-07-17 2014-09-12 Japan Tobacco, Inc. Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
US20150239889A1 (en) 2012-08-23 2015-08-27 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compound

Also Published As

Publication number Publication date
CA2979024A1 (en) 2016-09-22
DK3271357T3 (da) 2020-02-17
CR20170468A (es) 2018-04-27
HK1249512A1 (en) 2018-11-02
SG11201707280VA (en) 2017-10-30
PE20180656A1 (es) 2018-04-17
EP3271357A1 (en) 2018-01-24
ZA201706612B (en) 2019-01-30
CL2017002354A1 (es) 2018-05-04
UA123668C2 (uk) 2021-05-12
EP3271357B1 (en) 2019-11-27
CN107531698A (zh) 2018-01-02
CN107531698B (zh) 2024-08-13
MX2017011902A (es) 2017-12-15
BR112017019653B1 (pt) 2023-10-03
NZ735631A (en) 2023-07-28
DOP2017000209A (es) 2017-10-15
HUE047918T2 (hu) 2020-05-28
PH12017501699A1 (en) 2018-03-12
EA201792057A1 (ru) 2018-04-30
CA2979024C (en) 2024-02-20
CO2017009353A2 (es) 2017-11-30
TN2017000384A1 (en) 2019-01-16
IL254277A0 (en) 2017-10-31
IL254277B (en) 2020-10-29
BR112017019653A2 (pt) 2018-05-15
AU2016234209A1 (en) 2017-10-12
AU2016234209B2 (en) 2020-08-27
JP2018512408A (ja) 2018-05-17
WO2016148306A1 (en) 2016-09-22
US20180072714A1 (en) 2018-03-15
US10287286B2 (en) 2019-05-14
KR102609431B1 (ko) 2023-12-04
GEP20207095B (en) 2020-04-10
MY194873A (en) 2022-12-21
EA035739B1 (ru) 2020-08-03
ES2774052T3 (es) 2020-07-16
PT3271357T (pt) 2020-02-21
KR20170129874A (ko) 2017-11-27
JP6726681B2 (ja) 2020-07-22
ECSP17069696A (es) 2018-02-28
PH12017501699B1 (en) 2023-06-30

Similar Documents

Publication Publication Date Title
ZA201804739B (en) Novel compounds
IL255067A0 (en) new compounds
GB201516243D0 (en) Novel compounds
GB201522768D0 (en) Novel compounds
GB201506871D0 (en) Novel compounds
GB201521109D0 (en) Novel compounds
GB201501462D0 (en) Novel compounds
GB201510019D0 (en) Compounds
GB201522179D0 (en) Novel compounds
GB201504565D0 (en) Novel compounds
GB201508747D0 (en) Compounds
GB201514754D0 (en) Compounds
GB201514751D0 (en) Compounds
GB201508864D0 (en) Compounds
GB201502675D0 (en) Novel compounds
GB201510493D0 (en) Compounds
GB201503926D0 (en) Compounds
GB201501115D0 (en) Compounds
GB201508857D0 (en) Compounds
GB201521749D0 (en) Novel compounds
GB201521713D0 (en) Novel compounds
GB201516241D0 (en) Novel compounds
GB201512829D0 (en) Novel compounds
GB201512270D0 (en) Novel Compounds
GB201511842D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)